RxDoctor Payments Data

Frank McGeehin, MD

Interventional Cardiology · Wynnewood, PANPI 1598760340

Payments from drug & device makers

$3,303in general payments, 2019–2025

Across 149 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$803
  • AstraZeneca$529
  • Boston Scientific$495
  • Novartis$239
  • E.r. Squibb & Sons, L.L.C.$159
  • Pfizer$153
  • plus $924 from 19 others

What the payments were for

  • Food & beverage$3,303100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,303 in reported general payments places this provider in the 25th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$432,436
Medicare patients
1,216
Services billed
4,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban433$519,893
XareltoRivaroxaban171$189,462
JardianceEmpagliflozin154$188,557
EntrestoSacubitril/Valsartan125$172,871
Repatha SureclickEvolocumab117$145,889
Praluent PenAlirocumab41$35,635
FarxigaDapagliflozin Propanediol27$31,858
Rosuvastatin Calcium1,502$25,289
Metoprolol Succinate1,351$24,430
BrilintaTicagrelor15$15,735
Nebivolol Hcl153$9,665
Atorvastatin Calcium716$9,314
Losartan Potassium579$7,068
ClopidogrelClopidogrel Bisulfate488$6,916
LivaloPitavastatin Calcium11$5,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$519,893433 claims
Johnson & JohnsonXarelto$85$189,462171 claims
Boehringer IngelheimJardiance$95$188,557154 claims
NovartisEntresto$239$172,871125 claims
AstraZenecaFarxiga, Brilinta$529$47,59442 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$5,98911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →